Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

aTYR PHARMA (ATYR) Non Operating Income (2019 - 2025)

aTYR PHARMA's Non Operating Income history spans 7 years, with the latest figure at $832000.0 for Q4 2025.

  • For Q4 2025, Non Operating Income fell 2.35% year-over-year to $832000.0; the TTM value through Dec 2025 reached $3.5 million, down 9.97%, while the annual FY2025 figure was $3.5 million, 9.97% down from the prior year.
  • Non Operating Income reached $832000.0 in Q4 2025 per ATYR's latest filing, down from $999000.0 in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $1.3 million in Q3 2023 to a low of $47000.0 in Q1 2021.
  • Average Non Operating Income over 5 years is $660850.0, with a median of $833500.0 recorded in 2023.
  • Peak YoY movement for Non Operating Income: soared 1480.0% in 2021, then crashed 30.71% in 2024.
  • A 5-year view of Non Operating Income shows it stood at $79000.0 in 2021, then soared by 440.51% to $427000.0 in 2022, then skyrocketed by 180.56% to $1.2 million in 2023, then fell by 28.88% to $852000.0 in 2024, then dropped by 2.35% to $832000.0 in 2025.
  • Per Business Quant, the three most recent readings for ATYR's Non Operating Income are $832000.0 (Q4 2025), $999000.0 (Q3 2025), and $781000.0 (Q2 2025).